Aminolevulinic Acid
Diagnostic / imaging agent targets HMOX1 via activation
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | AMELUZ | — | 2024-10-04 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | LEVULAN | — | 2010-03-12 – 2018-03-06 | fda.gov ↗ |
| Approved | EU (EMA) | Gliolan | — | 2007-09-07 | europa.eu ↗ |
| Approved | US (FDA) | LEVULAN | — | 1999-12-03 | fda.gov ↗ |
Trials 118 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07038278 | Apr 2026 → Nov 2027 expected | soft tissue sarcoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07076472 | Aug 2025 → Dec 2026 expected | glioblastoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 0 | NCT03281811 | Nov 2017 → Feb 2020 | mycosis fungoides | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT00663910 | Mar 2008 → Oct 2009 | skin carcinoma | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 121 trials | ||||||
| Phase 1 | NCT07053852 | Jun → Dec 2025 | actinic keratosis, radiation-induced disorder | Sherrif Ibrahim | Completed | No outcome recorded |
| Phase 1 | NCT06665724 | Jan 2025 → Feb 2026 | anaplastic astrocytoma, anaplastic oligodendroglioma, glioblastoma | University of Münster | Completed | No outcome recorded |
| Phase 1 | NCT06623201 | Oct 2024 → Dec 2026 expected | basal cell carcinoma | Nathalie Zeitouni | Recruiting | No outcome recorded |
| Phase 1 | NCT06252727 | Jul 2024 → Feb 2026 | soft tissue sarcoma | University of California, Davis | Withdrawn | No outcome recorded |
| Phase 1 | NCT06039709 | Jan 2024 → Dec 2026 expected | glioblastoma | Shayan Moosa, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05362409 | Jun 2022 → Dec 2024 | malignant glioma | Alpheus Medical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05060237 | Dec 2021 → Apr 2023 | actinic keratosis, keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04044898 | Jan → Jul 2021 | acne | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04381806 | Jul 2020 → Feb 2027 | neoplasm | Fox Chase Cancer Center | Suspended | No outcome recorded |
| Phase 1 | NCT04319159 | Mar → Sep 2020 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 1 | NCT02191488 | Jul 2014 → Dec 2025 overdue | brain neoplasm | David W. Roberts | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01502605 | Sep 2012 → May 2015 | astrocytoma (excluding glioblastoma) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded |
| Phase 1 | NCT01697670 | Sep → Dec 2012 | ulcerative colitis | University of Zurich | Unknown | No outcome recorded |
| Phase 1 | NCT01682811 | Mar 2012 → Oct 2015 | neurofibromatosis type 1 | Harry T Whelan, MD | Completed | No outcome recorded |
| Phase 1 | NCT01148966 | Jun 2010 → Apr 2012 | adult glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, giant cell glioblastoma +1 | University of Washington | Terminated | No outcome recorded |
| Phase 1 | NCT01611584 | Jun 2010 → Jul 2014 | lung cancer | Dartmouth-Hitchcock Medical Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT01689935 | Nov 2009 → Sep 2013 | acne | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00978081 | Jan 2009 → Nov 2016 | head and neck cancer, precancerous condition | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00671710 | Apr 2008 → Nov 2010 | malignant glioma | Advocate Hospital System | Completed | No outcome recorded |
| Phase 1 | NCT00571558 | Mar 2008 → Jun 2010 | oral mucosa leukoplakia | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT00870779 | May 2007 → Jul 2012 | brain neoplasm | David W. Roberts | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT06307548 | Jul 2024 → Jun 2027 expected | colorectal carcinoma | Roswell Park Cancer Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05736406 | Feb 2024 → Mar 2026 overdue | glioblastoma | Hemerion Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05590689 | Nov 2022 → Jan 2028 expected | glioblastoma | University of Münster | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04164849 | Nov 2019 → Oct 2023 | Crohn disease | University Hospital, Akershus | Completed | No outcome recorded |
| Phase 1/2 | NCT03109353 | Sep 2017 → Dec 2022 | chronic graft versus host disease, primary cutaneous T-cell lymphoma | St. Olavs Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03110159 | Aug 2017 → Feb 2024 | actinic keratosis, hyperpigmentation of the skin, skin carcinoma | Medical Dermatology Specialists | Completed | No outcome recorded |
| Phase 1/2 | NCT03638622 | Mar 2017 → Oct 2020 | oral cavity cancer | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02367547 | Mar 2015 → Sep 2018 | basal cell carcinoma | Joint Authority for Päijät-Häme Social and Health Care | Unknown | No outcome recorded |
| Phase 1/2 | NCT02050243 | Feb 2014 → Feb 2016 | central nervous system cancer | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| Phase 1/2 | NCT01522677 | Aug 2012 → May 2014 | colon carcinoma | Edward Nelson | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01128218 | Mar 2011 → Feb 2021 | brain neoplasm | Southern Illinois University | Completed | No outcome recorded |
| Phase 1/2 | NCT00977795 | Sep 2009 → Jan 2010 | brain neoplasm | Endeavor Health | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00571974 | Jan 2007 → Jan 2012 | erythroplakia, leukoplakia | University of Arkansas | Completed | No outcome recorded |
| Phase 238 trials | ||||||
| Phase 2 | NCT06876038 | Sep 2026 → May 2028 expected | lichen planus, oral, oral cavity squamous cell carcinoma, oral mucosa leukoplakia | University of Massachusetts, Boston | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07657975 | Sep 2026 → Sep 2028 expected | epilepsy | Hospices Civils de Lyon | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06907485 | Aug 2026 → Feb 2028 expected | brain neoplasm | Costas Hadjipanayis | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06948552 | Apr 2026 → Dec 2027 expected | renal pelvis/ureter urothelial carcinoma | Henry Ford Health System | Recruiting | No outcome recorded |
| Phase 2 | NCT07225621 | Jan 2026 → Dec 2027 expected | glioblastoma | Alpheus Medical, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06678867 | Mar 2025 → Jun 2026 overdue | brain neoplasm | University College, London | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06577311 | Aug 2024 → Aug 2025 overdue | skin squamous cell carcinoma | The Center for Clinical and Cosmetic Research | Recruiting | No outcome recorded |
| Phase 2 | NCT06159842 | Aug 2023 → Sep 2024 | skin squamous cell carcinoma in situ | The Center for Clinical and Cosmetic Research | Completed | No outcome recorded |
| Phase 2 | NCT04845919 | Feb 2023 → Oct 2024 | glioblastoma | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Completed | No outcome recorded |
| Phase 2 | NCT05080764 | Dec 2021 → Aug 2025 | acne | Biofrontera Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05101798 | Sep 2021 → Dec 2022 | skull base neoplasm | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded |
| Phase 2 | NCT03897491 | Sep 2021 → Apr 2026 | glioblastoma | photonamic GmbH & Co. KG | Terminated | No outcome recorded |
| Phase 2 | NCT04469699 | Apr 2021 → Jan 2025 | adult glioblastoma | University Hospital Muenster | Terminated | No outcome recorded |
| Phase 2 | NCT07027670 | Feb 2021 → Jun 2022 | aortic valve disorder, coronary artery disorder, mitral valve disorder | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT04738162 | Sep 2020 → Nov 2025 | brain neoplasm | University of Münster | Completed | No outcome recorded |
| Phase 2 | NCT04020653 | Sep 2019 → May 2020 | malaria | Neopharma Japan Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03606122 | Jul 2018 → Jul 2019 | actinic keratosis | photonamic GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT02728388 | Sep 2016 → Dec 2025 | neurofibromatosis type 1 | Donald Basel | Terminated | No outcome recorded |
| Phase 2 | NCT02691923 | Mar 2016 → Dec 2025 overdue | brain cancer | David W. Roberts | Recruiting | No outcome recorded |
| Phase 2 | NCT02628236 | Feb → May 2016 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01445691 | Nov 2015 → Sep 2016 | benign neoplasm of brain, brain cancer, glioblastoma, primary brain neoplasm | Constantinos Hadjipanayis | Withdrawn | No outcome recorded |
| Phase 2 | NCT02355899 | Jan 2015 → Aug 2017 | tinea unguium | photonamic GmbH & Co. KG | Completed | No outcome recorded |
| Phase 2 | NCT02281136 | Dec 2014 → Apr 2015 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02239679 | Sep 2014 → Jul 2016 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01898416 | Jun 2013 → Dec 2023 overdue | desmoid tumor caused by somatic mutation | michal roll | Recruiting | No outcome recorded |
| Phase 2 | NCT01575275 | May 2012 → May 2014 | adult glioblastoma, giant cell glioblastoma, gliosarcoma | Michael Vogelbaum, MD, PhD | Terminated | No outcome recorded |
| Phase 2 | NCT01475955 | Dec 2011 → Nov 2012 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01458587 | Nov 2011 → Jul 2012 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01351519 | May 2011 → Jan 2015 | astrocytoma (excluding glioblastoma), glioblastoma | MultiCare Health System Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT01403311 | Oct 2010 → Dec 2011 | glioma | Legacy Health System | Unknown | No outcome recorded |
| Phase 2 | NCT01116661 | Aug 2010 → Dec 2017 | glioma | University of California, San Francisco | Terminated | No outcome recorded |
| Phase 2 | NCT00752323 | Dec 2009 → Sep 2018 | central nervous system cancer | Andrew Sloan, MD | Completed | No outcome recorded |
| Phase 2 | NCT00961090 | Sep 2009 → Apr 2015 | glioblastoma | Matthew R Quigley | Completed | No outcome recorded |
| Phase 2 | NCT00747903 | Feb 2008 → Dec 2010 | skin cancer | Laser and Skin Surgery Center of New York | Unknown | No outcome recorded |
| Phase 2 | NCT02799030 | Oct 2006 → Mar 2007 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00054171 | Feb 1999 → Jul 2005 | leukemia, lymphoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00002975 | Feb 1997 → Apr 2009 | epithelial skin neoplasm, precancerous condition | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00002963 | Nov 1993 → Jun 2007 | skin carcinoma | Roswell Park Cancer Institute | Completed | No outcome recorded |
| Phase 317 trials | ||||||
| Phase 3 | NCT07144852 | Nov 2025 → Jan 2027 expected | actinic keratosis | Sun Pharmaceutical Industries, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07144345 | Nov 2025 → Jan 2027 expected | actinic keratosis | Sun Pharmaceutical Industries, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06160492 | Apr 2025 → Feb 2026 overdue | — | Lee's Pharmaceutical Limited | Recruiting | No outcome recorded |
| Phase 3 | NCT06417281 | Jun 2024 → Aug 2025 | malignant glioma, porphyria due to ALA dehydratase deficiency | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT05804370 | May 2024 → Sep 2028 expected | ovarian cancer | NX Development Corp | Recruiting | No outcome recorded |
| Phase 3 | NCT05662202 | Dec 2022 → Sep 2025 | actinic keratosis | Biofrontera Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04815083 | Apr 2021 → Oct 2024 | breast cancer | SBI ALApharma Canada, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT04305470 | Oct 2020 → Nov 2022 | meningioma | NX Development Corp | Completed | No outcome recorded |
| Phase 3 | NCT04636242 | Aug 2019 → Aug 2021 | — | Rothman Institute Orthopaedics | Unknown | No outcome recorded |
| Phase 3 | NCT03573401 | Sep 2018 → Mar 2024 overdue | skin basal cell carcinoma | Biofrontera Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02137785 | May 2014 → Mar 2015 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02101931 | Mar 2014 → Mar 2016 | bladder transitional cell carcinoma | Princess Al-Johara Al-Ibrahim Cancer Research Center | Completed | No outcome recorded |
| Phase 3 | NCT01811121 | Feb → Mar 2013 | glioblastoma | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 3 | NCT01459393 | Nov 2010 → Nov 2011 | actinic keratosis | Barretos Cancer Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01502280 | Nov 2010 → Jan 2018 | glioma | St. Joseph's Hospital and Medical Center, Phoenix | Completed | No outcome recorded |
| Phase 3 | NCT01167322 | Aug 2010 → Dec 2011 | malignant glioma | Nobelpharma | Completed | No outcome recorded |
| Phase 3 | NCT00241670 | Oct 1999 → Jul 2004 | brain cancer, primary brain neoplasm | medac GmbH | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT06745999 | May 2023 → May 2025 | actinic keratosis | Psoriasis Treatment Center of Central New Jersey | Unknown | No outcome recorded |
| Phase 4 | NCT05359419 | May 2022 → Aug 2023 | skin neoplasm | Goldman, Butterwick, Fitzpatrick and Groff | Unknown | No outcome recorded |
| Phase 4 | NCT03963102 | Oct 2019 → Mar 2024 | actinic keratosis | Royal Cornwall Hospitals Trust | Terminated | No outcome recorded |
| Phase 4 | NCT04221126 | Apr → Aug 2019 | — | Merete Haedersdal | Completed | No outcome recorded |
| Phase 4 | NCT02685592 | Feb 2016 → Mar 2018 | lentigo | Joint Authority for Päijät-Häme Social and Health Care | Completed | No outcome recorded |
| Phase 4 | NCT02647151 | Dec 2015 → Mar 2016 | actinic keratosis | Fundación Instituto Valenciano de Oncología | Unknown | No outcome recorded |
| Phase 4 | NCT02464709 | Jun 2015 → Oct 2017 | actinic keratosis | Joint Authority for Päijät-Häme Social and Health Care | Completed | No outcome recorded |
| Phase 4 | NCT03327831 | Apr 2015 → Feb 2017 | actinic keratosis | University of California, Irvine | Completed | No outcome recorded |
| Phase 4 | NCT02409732 | Apr 2015 → Jul 2017 | actinic cheilitis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02075671 | Apr 2014 → Aug 2019 | rosacea | George Washington University | Completed | No outcome recorded |
| Phase 4 | NCT01893203 | Aug 2013 → Dec 2014 | actinic keratosis | Joint Authority for Päijät-Häme Social and Health Care | Completed | No outcome recorded |
| Phase 4 | NCT01203878 | Sep 2010 → Nov 2011 | actinic keratosis | Tennessee Clinical Research Center | Terminated | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT05228483 | Nov 2021 → Nov 2023 | vulvar lichen sclerosus | Xijing Hospital | Unknown | No outcome recorded |
| — | NCT07536737 | Sep 2021 → Jan 2023 | lichen planus, oral | Medical University of Bialystok | Completed | No outcome recorded |
| — | NCT02867722 | Dec 2020 → Dec 2021 | actinic keratosis, skin cancer | Brigham and Women's Hospital | Withdrawn | No outcome recorded |
| — | NCT04631250 | Nov 2018 → Jul 2020 | acne | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT03048240 | May 2017 → Apr 2021 | glioblastoma | University Hospital, Lille | Completed | No outcome recorded |
| — | NCT03066843 | Mar 2017 → Aug 2023 | actinic keratosis | Northwestern University | Completed | No outcome recorded |
| — | NCT03025724 | Jan 2017 → Jan 2020 | skin squamous cell carcinoma | Rhode Island Hospital | Unknown | No outcome recorded |
| — | NCT02157623 | Feb → Sep 2016 | nevoid basal cell carcinoma syndrome | Edward Maytin, MD, PhD | Completed | No outcome recorded |
| — | NCT02594644 | Nov 2014 → Jun 2016 | actinic keratosis | University of California, Davis | Completed | No outcome recorded |
| — | NCT02119338 | Feb 2014 → Jun 2017 | glioma | St. Joseph's Hospital and Medical Center, Phoenix | Unknown | No outcome recorded |
| — | NCT01812837 | Jul 2012 → Mar 2014 | actinic keratosis | University of California, Davis | Completed | No outcome recorded |
| — | NCT00814528 | Nov 2007 → Sep 2009 | actinic keratosis | University of Chicago | Withdrawn | No outcome recorded |
| — | NCT00524485 | May 2005 → Jan 2009 | precancerous condition | Roswell Park Cancer Institute | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 19 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03114111 Comparator | Jan 2017 → Dec 2019 | seborrheic dermatitis | University of California, Davis | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT02698293 Background | Dec 2019 → Jan 2023 | anus disorder, in situ carcinoma | Abramson Cancer Center at Penn Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03322293 Background | Dec 2017 → Dec 2018 | actinic keratosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02755142 Comparator | Feb 2000 → Jun 2001 | brain neoplasm | medac GmbH | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04391062 Background | Sep 2021 → Mar 2024 | glioblastoma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2 | NCT01556009 Comparator | Apr 2012 → Dec 2015 | nevoid basal cell carcinoma syndrome | UCSF Benioff Children's Hospital Oakland | Completed | No outcome recorded |
| Phase 2 | NCT00865878 Comparator | May 2009 → Sep 2011 | actinic keratosis | DUSA Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00706433 Comparator | Mar 2007 → Jul 2008 | acne | DUSA Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02144077 Comparator | Jan 2014 → Nov 2015 | basal cell carcinoma | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 3 | NCT01966120 Comparator | Oct 2013 → Sep 2014 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02799069 Comparator | Apr 2008 → Aug 2009 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 3 | NCT02799082 Comparator | Dec 2007 → Oct 2008 | actinic keratosis | Biofrontera Bioscience GmbH | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02622594 Comparator | Oct 2015 → Apr 2017 | actinic keratosis | Dermatology, Laser & Vein Specialists of the Carolinas | Completed | No outcome recorded |
| Phase 4 | NCT01491711 Comparator | Aug 2013 → Apr 2015 | superficial multifocal basal cell carcinoma | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT05488860 Background | Jul 2022 → Jun 2024 | keloid, plantar wart | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| — | NCT02644187 Background | Dec 2015 → Mar 2017 | actinic keratosis | Vastra Gotaland Region | Completed | No outcome recorded |
| — | NCT02379572 Comparator | Jun 2015 → Jun 2020 | glioblastoma | University Hospital Tuebingen | Completed | No outcome recorded |
| — | NCT02481141 Comparator | Jul 2014 → Jul 2015 | type 2 diabetes mellitus | SBI Pharmaceuticals Co, Ltd. | Completed | No outcome recorded |
| — | NCT00814918 Background | Feb 2009 → Feb 2013 | acne | University of Chicago | Withdrawn | No outcome recorded |
Evidence & citations 37 cited values
Every value below carries the sentence it was read from. 146 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aminolevulinic acid | “Aminolevulinic acid 20% solution with blue light photodynamic therapy (ALA-PDT) has previously been shown to be superior to vehicle plus PDT (VEH-PDT) for treatment of AKs of...” PMID 38125671 ↗ Dec 202350“Aminolevulinic Acid (ALA) preparation and administration: The FDA-approved Aminolevulinic Acid (ALA) from Dusa Pharmaceuticals, Inc., Wilmington, Massachusetts (MA) will be...” NCT03638622 ↗ “PDT treatment consists of applying a gel containing aminolevulinic acid hydrochloride (licensed for clinical use as Ameluz®) to the abnormal area.” NCT03963102 ↗ “A Pharmacokinetics and Safety Study of Aminolevulinic Acid Hydrochloride Topical Powder in Subjects With Moderate to Severe Facial Acne Vulgaris.” NCT04044898 ↗ “A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer” NCT01611584 ↗ “Photodynamic therapy with aminolevulinic acid (ALA) 20% topical solution is also an approved treatment for actinic keratoses.” NCT01203878 ↗ “The purpose of this study is to improve the current ECP technology using aminolevulinic acid (ALA) and UV light.” NCT03109353 ↗ “previous severe adverse reaction to topical 20% aminolevulinic acid (Kerastick)” NCT03025724 ↗ “10% aminolevulinic acid gel (Ameluz®, BF-200 ALA)” NCT05662202 ↗ |
| Known as | .delta.-aminolevulinic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Known as | .delta.-aminolevulinic acid hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Known as | 5 ala hcl (trivial name) | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Known as | 5-ALA | “This is a prospective, single-arm feasibility study investigating the use of 5-aminolevulinic acid (5-ALA, Gleolan) to enhance intraoperative tumor visualization in patients...” NCT06948552 ↗37“The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with...” NCT04391062 ↗ “patient will be instructed to apply 5-aminolevulinic acid HCL topical solution to their shoulder prior to their surgery. 16 minutes before skin incision a blue light will be...” NCT04636242 ↗ “Only one phase III prospective randomized study, published in 2006, has assessed the performance of 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) for...” PMID 37856381 ↗ Oct 2023 “Here, we present a safety and feasibility trial after treating GBM intraoperatively by photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal...” PMID 33743128 ↗ Mar 2021 “5-aminolevulinic acid (5-ALA) is a photosensitizing agent which can induce photochemical reactions in tissues in response to an appropriate wavelength of light (red light 630-635nm).” NCT05228483 ↗ “This study is intended to investigate the utility, safety and efficacy of 5-aminolevulinic acid (5-ALA) induced brain tumor fluorescence during malignant brain tumor resection.” NCT00977795 ↗ “A multifaceted treatment approach can include nutritional supplements with antioxidant properties such as 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC).” PMID 27738640 ↗ Sep 2016 “BACKGROUND: 5-aminolevulinic acid (5-ALA; GleolanTM, NX Development Corps., Lexington, USA) is approved for fluorescence-guided resections of suspected malignant gliomas.” PMID 36009108 ↗ Aug 2022 “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.” NCT05080764 ↗ “5-aminolevulinic acid (5-ALA) has been shown to be valuable in intraoperative marking of various cancers.” NCT02050243 ↗ “All patients will receive 5-aminolevulinic acid (5-ALA) in combination with blue light photopheresis.” NCT04164849 ↗ “using oral 5-aminolevulinic Acid (5-ALA) which results in fluorescence of the malignant cells” NCT01128218 ↗ “PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².” NCT02355899 ↗ “PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm²” NCT03606122 ↗ “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).” NCT05662202 ↗ “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).” NCT03573401 ↗ “single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder” NCT06417281 ↗ “5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.” NCT01898416 ↗ “5-aminolevulinic acid (5-ALA) (also known as Gliolan)” NCT01502605 ↗ “containing 7.8% 5-ALA (5-aminolevulinic acid)” NCT04319159 ↗ “5-Aminolevulinic Acid hydrochloride (5-ALA)” NCT07027670 ↗ “5-aminolevulinic acid (5-ALA)” NCT00241670 ↗ |
| Known as | 5-ALA HCL | “We report updated, exploratory analyses of OS, PFS, and health-related quality of life (HRQOL) for patients receiving intraoperative photodynamic therapy (PDT) with...” PMID 38753093 ↗ May 20243“5-ALA HCl (5-amino-levulenic acid) for oral solution (20 mg/kg) p.o. 6-8 hours prior to LIDU SDT” NCT07225621 ↗ “or orally administered aminolevulinic acid hydrochloride (5-ALA HCL)” NCT07076472 ↗ “5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®)” NCT06665724 ↗ |
| Known as | 5-ALA, 5-aminolevulic acid hydrochloride | “5-ALA, 5-aminolevulic acid hydrochloride” NCT01167322 ↗ |
| Known as | 5-amino-levulenic acid | “5-ALA HCl (5-amino-levulenic acid) for oral solution (20 mg/kg) p.o. 6-8 hours prior to LIDU SDT” NCT07225621 ↗ |
| Known as | 5-aminolaevulinic acid | “Following topical application of 5-aminolaevulinic acid, the substance is metabolized to protoporphyrin IX, a photoactive compound which accumulates intracellularly in the...” NCT02647151 ↗ |
| Known as | 5-aminolevulinic acid | “This is a prospective, randomized controlled trial to evaluation the ability of 5-aminolevulinic acid HCL topical solution photodynamic therapy to decrease the colonization of...” NCT04636242 ↗54“The aim of this study is to test the effectiveness and safety of the medicine Ameluz® (5-aminolevulinic acid) in comparison to methyl-aminolevulinate (MAL), used with...” NCT02144077 ↗ “The drug, 5-aminolevulinic acid (ALA), which leads to intracellular accumulation of fluorescent porphyrins in gliomas will be used under investigation for identification and...” NCT01116661 ↗ “Only one phase III prospective randomized study, published in 2006, has assessed the performance of 5-aminolevulinic acid (5-ALA) fluorescence-guided surgery (FGS) for...” PMID 37856381 ↗ Oct 2023 “Here, we present a safety and feasibility trial after treating GBM intraoperatively by photodynamic therapy (PDT) after 5-aminolevulinic acid (5-ALA) administration and maximal...” PMID 33743128 ↗ Mar 2021 “BACKGROUND: 5-aminolevulinic acid (5-ALA; GleolanTM, NX Development Corps., Lexington, USA) is approved for fluorescence-guided resections of suspected malignant gliomas.” PMID 36009108 ↗ Aug 2022 “A multifaceted treatment approach can include nutritional supplements with antioxidant properties such as 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC).” PMID 27738640 ↗ Sep 2016 “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid) red light photodynamic therapy (PDT) utilizing BF-RhodoLED® after 1h incubation.” NCT05080764 ↗ “5-aminolevulinic acid (5-ALA) fluorescence-guided resection of high-grade gliomas (HGG) increases the extent of resection (EOR) and progression-free survival.” PMID 36656388 ↗ Jan 2023 “The aim of this study is to assess the pharmacokinetics (PK) of the parent drug 5-aminolevulinic acid (ALA) and its active metabolite protoporphyrin IX (PpIX)” NCT04319159 ↗ “This study aims to determine the safety and utility of using 5-Aminolevulinic Acid (ALA) in removing malignant brain tumors during surgery.” NCT01403311 ↗ “For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery.” NCT02379572 ↗ “5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration.” NCT02698293 ↗ “5-aminolevulinic acid (5-ALA) associated with 20% dimethyl sulfoxide (DMSO) and 3% ethylene diamine acid (EDTA) emulsion” NCT01459393 ↗ “ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation” NCT03066843 ↗ “orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)” NCT04381806 ↗ “A 5% 5-aminolevulinic acid (ALA) mucoadhesive formulation is applied topically to oral lichen planus lesions.” NCT07536737 ↗ “5-aminolevulinic acid (5-ALA) has been shown to be valuable in intraoperative marking of various cancers.” NCT02050243 ↗ “5-aminolevulinic acid hydrochloride (5-ALA HCl) administration + brain cavity illumination” NCT05736406 ↗ “Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA).” NCT02799069 ↗ “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).” NCT03573401 ↗ “Topical application of BF-200 ALA containing 7.8% 5-ALA (5-aminolevulinic acid).” NCT05662202 ↗ “5-aminolevulinic acid \[5-ALA\] administered orally 20 mg/kg every 4 weeks” NCT05362409 ↗ “BF-200 ALA (containing the active ingredient 5 - aminolevulinic acid- ALA)” NCT02799030 ↗ “single oral dose of 5-aminolevulinic acid (5-ALA) oral solution powder” NCT06417281 ↗ “Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1” NCT01682811 ↗ “naturally occurring amino acid, 5-aminolevulinic acid (5-ALA)” NCT01128218 ↗ “Flourescein = Fluorescite; ALA = 5-Aminolevulinic Acid” NCT02691923 ↗ “5-aminolevulinic acid compounded in a cream” NCT04221126 ↗ |
| Known as | 5-aminolevulinic acid HCL | “This is a prospective, randomized controlled trial to evaluation the ability of 5-aminolevulinic acid HCL topical solution photodynamic therapy to decrease the colonization of...” NCT04636242 ↗ |
| Known as | 5-Aminolevulinic Acid hydrochloride | “The patient will receive 5-ALA ( 5-aminolevulinic acid hydrochloride),GLIOLAN drinkable 6h before surgery + lighting of the tumor bed by a red light source (laser with...” NCT04391062 ↗6“We report updated, exploratory analyses of OS, PFS, and health-related quality of life (HRQOL) for patients receiving intraoperative photodynamic therapy (PDT) with...” PMID 38753093 ↗ May 2024 “NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence” NCT01167322 ↗ “5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®)” NCT06665724 ↗ “5-Aminolevulinic acid Hydrochloride (Gliolan®)” NCT06948552 ↗ “5-Aminolevulinic Acid hydrochloride (5-ALA)” NCT07027670 ↗ |
| Known as | 5-aminolevulinic acid nanoemulsion | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02685592 ↗ |
| Known as | 5-aminolévulinique acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01811121 ↗ |
| Known as | ALA | “The drug, 5-aminolevulinic acid (ALA), which leads to intracellular accumulation of fluorescent porphyrins in gliomas will be used under investigation for identification and...” NCT01116661 ↗25“The objective of this study was to detect 5-aminolevulinic acid (ALA)-induced tumor fluorescence from glioma below the surface of the surgical field by using red-light illumination.” PMID 28777025 ↗ Aug 2017 “Individual lesions on patients within each stratum are randomized to receive either a 4-5 or 18-24 hour application of aminolevulinic acid (ALA).” NCT00002975 ↗ “This study aims to determine the safety and utility of using 5-Aminolevulinic Acid (ALA) in removing malignant brain tumors during surgery.” NCT01403311 ↗ “The nanoemulsion-based 10% aminolevulinic acid (ALA) hydrochloride gel BF-200 ALA optimizes epidermal penetration of its active ingredient” PMID 34633154 ↗ Oct 2021 “A Proof of Principle Study of Aminolevulinic Acid (ALA) - Induced Fluorescence Detection in Resectable Non-Small Cell Lung Cancer” NCT01611584 ↗ “topically applied aminolevulinic acid (ALA) into the lesions of patients with primary basal cell and squamous cell carcinomas.” NCT00002963 ↗ “Photodynamic therapy with aminolevulinic acid (ALA) 20% topical solution is also an approved treatment for actinic keratoses.” NCT01203878 ↗ “PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent.” NCT03322293 ↗ “Aminolevulinic acid (ALA) is a naturally occurring metabolite in the synthesis of pathway of cellular heme production.” NCT04636242 ↗ “20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light.” NCT00865878 ↗ “orally-administered 5-aminolevulinic acid (ALA) given as a radiosensitizer prior to low-dose radiation therapy (RT)” NCT04381806 ↗ “The purpose of this study is to improve the current ECP technology using aminolevulinic acid (ALA) and UV light.” NCT03109353 ↗ “A 5% 5-aminolevulinic acid (ALA) mucoadhesive formulation is applied topically to oral lichen planus lesions.” NCT07536737 ↗ “Photodynamic therapy (PDT) uses a drug called ALA (aminolevulinic acid), which is marketed as Levulan®.” NCT01689935 ↗ “Topical application of BF-200 ALA gel containing 78 mg/g 5-aminolevulinic acid (ALA).” NCT02799069 ↗ “Aminolevulinic Acid 20% Topical Solution (Levulan® Kerastick® Applicators) (ALA)” NCT06159842 ↗ “Patients receive topical ALA topical (aminolevulinic acid) 2 hours before PDT.” NCT00524485 ↗ “BF-200 ALA (containing the active ingredient 5 - aminolevulinic acid- ALA)” NCT02799030 ↗ “aminolevulinic acid HCL (ALA)” NCT06623201 ↗ “Aminolevulinic Acid PDT (ALA)” NCT01458587 ↗ “Aminolevulinic Acid (ALA)” NCT02137785 ↗ “Aminolevulinic Acid (ALA)” NCT02628236 ↗ “Aminolevulinic Acid (ALA)” NCT02622594 ↗ |
| Known as | ALA HCl | “Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%” NCT07144345 ↗ |
| Known as | Alabel | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Known as | Alaglio | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Known as | Ameluz | “PDT treatment consists of applying a gel containing aminolevulinic acid hydrochloride (licensed for clinical use as Ameluz®) to the abnormal area.” NCT03963102 ↗8“A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.” NCT02464709 ↗ “using 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream” NCT02685592 ↗ “AMELUZ® (aminolevulinic acid hydrochloride) gel, 10%” NCT05359419 ↗ “10% aminolevulinic acid gel (Ameluz®, BF-200 ALA)” NCT05662202 ↗ “BF-200 ALA 10% gel (Ameluz®)” NCT04319159 ↗ “BF-200 ALA (Ameluz®)” NCT05060237 ↗ |
| Known as | Aminolevulinic acid (ALA) | “Aminolevulinic acid (ALA)” NCT03638622 ↗ |
| Known as | aminolevulinic acid HCL | “A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions” NCT02628236 ↗5“20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light.” NCT00865878 ↗ “Drug intervention: Aminolevulinic acid HCl (ALA) topical solution 20%” NCT03322293 ↗ “LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution, 20%” NCT05359419 ↗ “aminolevulinic acid HCL (ALA)” NCT06623201 ↗ |
| Known as | aminolevulinic acid HCL (ALA) | “Levulan® Kerastick® containing 20% aminolevulinic acid HCL (ALA, active study drug)” NCT00706433 ↗ |
| Known as | aminolevulinic acid hydrochloride | “Participants will have their facial Cutaneous Squamous Cell Carcinoma in situ (SCCis) prepped then treated with Aminolevulinic acid hydrochloride 10% topical gel (Ameluz ®),...” NCT06577311 ↗8“AMINOLEVULINIC ACID HYDROCHLORIDE (ALA) gel 78mg/g. Intervention: Just one application of the product in the actinic keratosis lesions before the photodynamic therapy” NCT02647151 ↗ “Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%” NCT07144345 ↗ “AMELUZ® (aminolevulinic acid hydrochloride) gel, 10%” NCT05359419 ↗ “Drug: aminolevulinic acid hydrochloride” NCT00571558 ↗ |
| Known as | BF-200 ALA | “A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.” NCT02464709 ↗8“The nanoemulsion-based 10% aminolevulinic acid (ALA) hydrochloride gel BF-200 ALA optimizes epidermal penetration of its active ingredient” PMID 34633154 ↗ Oct 2021 “using 5-aminolevulinic acid nanoemulsion (BF-200 ALA, Ameluz®) as a light sensitizing cream” NCT02685592 ↗ “10% aminolevulinic acid gel (Ameluz®, BF-200 ALA)” NCT05662202 ↗ “Drug: BF200-ALA/5-aminolevulinic acid” NCT02644187 ↗ |
| Known as | Gleolan | “This is a prospective, single-arm feasibility study investigating the use of 5-aminolevulinic acid (5-ALA, Gleolan) to enhance intraoperative tumor visualization in patients...” NCT06948552 ↗3“The combination of 5-ALA (Gleolan) and LIFU is collectively known as sonodynamic therapy (SDT).” NCT06039709 ↗ |
| Known as | Gliolan | “an investigational agent, known as 5-ALA or Gliolan (aminolevulinic acid), that many be useful to a surgeon for visualizing a tumor during surgery” NCT01575275 ↗12“5-aminolevulinic acid hydrochloride (Gliolan), orally, 40 mg/kg administered approximately 4-6 hours before light administration.” NCT02698293 ↗ “3 millimolar 5 aminolevulinic acid (Gliolan®) in combination with blue-light (405 nanometer) photopheresis” NCT04164849 ↗ “patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery” NCT03048240 ↗ “5-aminolevulinic acid hydrochloride (5-ALA HCl, Gliolan®)” NCT06665724 ↗ “5-aminolevulinic acid (5-ALA) (also known as Gliolan)” NCT01502605 ↗ “5-Aminolevulinic acid Hydrochloride (Gliolan®)” NCT06948552 ↗ “5-ALA (Gliolan)” NCT07657975 ↗ “5-ALA (Gliolan)” NCT06678867 ↗ |
| Known as | Kerastick | “topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis” NCT03025724 ↗ |
| Known as | Levulan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01682811 ↗ |
| Known as | LEVULAN KERASTICK | “reformulated Levulan Kerastick (aminolevulinic acid HCl 20%) combined with photodynamic therapy (PDT) for field-directed treatment of actinic keratosis (AK) on the face or bald scalp.” NCT07144345 ↗3“20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes.” NCT00814918 ↗ “LEVULAN® KERASTICK® (aminolevulinic acid HCl) topical solution, 20%” NCT05359419 ↗ |
| Known as | Levulan Kerasticks (aminolevulinic acid 20% solution) | “Levulan Kerasticks (aminolevulinic acid 20% solution)” NCT01203878 ↗ |
| Known as | Levulan KerastickTM | “5-Aminolevulinic Acid (Levulan KerastickTM)” NCT00571974 ↗ |
| Known as | NPC-07 | “NPC-07 (5-aminolevulinic acid hydrochloride) induced tissue fluorescence” NCT01167322 ↗ |
| Known as | NSC-18509 | ChEMBL registry synonym — accepted as the source's own label CHEMBL601 ↗ |
| Action | Activate | “to induce haem oxygenase-1 (HO-1)” NCT07027670 ↗ |
| Modality | Other / unclassified | “Photodynamic therapy with 5-aminolevulinic acid and pulsed dye laser” PMID 22106236 ↗ Nov 2011 |
| Route | Topical | “Aminolevulinic acid is topically applied” NCT00002963 ↗ |
| Target | HMOX1 | “to induce haem oxygenase-1 (HO-1)” NCT07027670 ↗ |